Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.

Authors:
Address: National Institute for Public Health and the Environment (RIVM), Centre for infectious Diseases Control Netherlands, Section Vaccinology, Bilthoven, the Netherlands. patricia.kaaijk@rivm.nl
Journal:

Publication:

abstract

BACKGROUND:

the first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience substantial declines in the incidence of MenC disease.

DISCUSSION:

Since 2001, the MenC conjugate vaccine has been implemented in the Netherlands by offering a single dose to all children aged 14 months. Prior to the introduction of the vaccine into the national immunisation programme, a catch-up vaccination campaign was initiated in which a single dose of the MenC conjugate vaccine was offered to all children aged from 14 months up to and including 18 years. Since then, there has been no report of any case of MenC disease among immunocompetent vaccinees. Administration of a single dose of MenC conjugate vaccine after infancy could be beneficial considering the already complex immunisation schedules with large numbers of vaccinations in the first year of life. The present paper deals with the advantages and critical aspects of a single dose of the MenC conjugate vaccine.

SUMMARY:

A single dose of MenC conjugate vaccine at the age of 14 months in combination with a catch up vaccine campaign appeared to be a successful strategy to prevent MenC disease in the Netherlands, thereby confirming that a single dose of the vaccine could sufficiently protect against disease. Nevertheless, this approach can only be justified in countries with a relatively low incidence of serogroup C meningococcal disease in the first year of life. Furthermore, a good surveillance programme is recommended for timely detection of vaccine breakthroughs and outbreaks among non-vaccinees, since long-term protection after a single dose in the second year of life cannot currently be guaranteed.

Related Articles
Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
PLoS One. 2010
Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, Sanders EA, Berbers GA, van der Klis FR. PLoS One. 2010 Aug 13; 5(8):e12144. Epub 2010 Aug 13.
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.
Pediatr Infect Dis J. 2006
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.
de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Pediatr Infect Dis J. 2006 Jan; 25(1):79-80.
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Hum Vaccin. 2010
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Hum Vaccin. 2010 Aug; 6(8):640-51.
Review Meningococcal polysaccharide-protein conjugate vaccines.
Lancet Infect Dis. 2005
Review Meningococcal polysaccharide-protein conjugate vaccines.
Snape MD, Pollard AJ. Lancet Infect Dis. 2005 Jan; 5(1):21-30.
Review Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
Expert Rev Vaccines. 2006
Review Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
De Wals P. Expert Rev Vaccines. 2006 Apr; 5(2):269-75.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.